According to this latest study, the 2021 growth of Nanomaterial-Based Adjuvants Vaccine will have significant change from previous year. By the most conservative estimates of global Nanomaterial-Based Adjuvants Vaccine market size (most likely outcome) will be a year-over-year revenue growth rate of % in 2021, from US$ 14250 million in 2020. Over the next five years the Nanomaterial-Based Adjuvants Vaccine market will register a 38.8% CAGR in terms of revenue, the global market size will reach US$ 52900 million by 2026.
This report presents a comprehensive overview, market shares, and growth opportunities of Nanomaterial-Based Adjuvants Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Aluminium Hydroxides
Aluminium Phosphate
Lipidosome
Others
Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Pneumococcus
Human Papilloma Virus
DTaP
Viral Hepatitis TypeA
Viral Hepatitis TypeB
SARS-CoV-2
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna